Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20440210 | 0.94 | EPHX1 (0.46) | EPHX1HRH4HRH3SIGMAR1POLB | |
| SCHEMBL22352745 | 0.92 | CYP2C19 (0.43) | EPHX1HRH4HRH3SIGMAR1TP53BP1 | |
| SCHEMBL5839106 | 0.87 | HRH4 (0.39) | HRH4HRH3TP53BP1POLBMEN1 | |
| Hydrochloric Acid SCHEMBL6658209 | 0.81 | HRH4 (0.36) | HRH4HRH3TP53BP1POLBMEN1 | |
| SCHEMBL3318414 | 0.81 | — | — | |
| SCHEMBL24515164 | 0.81 | PRMT3 (0.37) | EPHX1 | |
| SCHEMBL7834390 | 0.81 | HRH4 (0.43) | HRH4HRH3TP53BP1POLBMEN1 | |
| SCHEMBL9238490 | 0.78 | KISS1R (0.36) | EPHX1SIGMAR1KISS1R | |
| SCHEMBL1276622 | 0.78 | HRH4 (0.45) | EPHX1HRH4HRH3TP53BP1POLB | |
| SCHEMBL18351665 | 0.78 | HRH4 (0.42) | HRH4HRH3TP53BP1POLBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073871-A1 | GSPT1 DEGRADERS, COMPOSITIONS COMPRISING THE DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-04-11 | — | — | WO | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685722-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| EP-3086792-B1 | METHODS AND REAGENTS FOR RADIOLABELING | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11242323-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | LOHOCLA RESEARCH CORPORATION (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20170029426-A1 | METHODS AND REAGENTS FOR RADIOLABELING | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160376587-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-9278987-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-8980221-B2 | Fluoride processing method | GE HEALTHCARE LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | SAREPTA THERAPEUTICS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-5977286-A | Amine-modified epoxy resin reacted with polyisocyanate | VIANOVA RESINS GMBH (DE) | 1999-11-02 | — | — | US | disclosed |
| EP-0819733-A2 | Amine-modified epoxy resin composition | Vianova Resins GmbH (DE) | 1998-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130737-B2 | Multifunctional aminoquinoline therapeutic agents | OPRK1, OPRM1, OPRD1 | EPHX1 1424/4885HRH4 350/4885HRH3 622/4885 |
| US-20210253535-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | EPHX1 532/4885HRH4 4616/4885HRH3 4049/4885 |
| US-11685722-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | EPHX1 532/4885HRH4 4616/4885HRH3 4049/4885 |
| US-20170029426-A1 | METHODS AND REAGENTS FOR RADIOLABELING | HSP90AB1, HSP90B1, HSP90AA1 | EPHX1 1635/4885HRH4 3468/4885HRH3 3835/4885 |
| US-11208655-B2 | Functionally-modified oligonucleotides and subunits thereof | RTCB, NSUN3, NSUN2 | EPHX1 3897/4885HRH4 4651/4885HRH3 4821/4885 |
| US-20140330006-A1 | FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF | RTCB, NSUN3, NSUN2 | EPHX1 3897/4885HRH4 4651/4885HRH3 4821/4885 |
| US-11242323-B2 | Inhibition of OLIG2 activity | POU2F2, ING2, PAX2 | EPHX1 814/4885HRH4 3936/4885HRH3 3112/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | EPHX1 3897/4885HRH4 4651/4885HRH3 4821/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | EPHX1 2877/4885HRH4 189/4885HRH3 177/4885 |
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | EPHX1 1924/4885HRH4 2880/4885HRH3 3143/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | EPHX1 3284/4885HRH4 1550/4885HRH3 1893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.